Point72 Asia (Singapore)’s Y-mAbs Therapeutics YMAB Stock Holding History

Point72 Asia (Singapore)’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,171	Closed	-$54.9K	–	1285
2025 Q2	$54.9K	Sell	12,171 -18,917	-61%	-$85K	0.01%	575
2025 Q1	$138K	Buy	+31,088	New	+$180K	0.04%	345
2024 Q2	–	Sell	-6,019	Closed	-$97.9K	–	1553
2024 Q1	$97.9K	Buy	+6,019	New	+$81.1K	0.03%	650

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Point72 Asia (Singapore)'s YMAB Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 12,171 shares — an estimated $54.9K sold.

Point72 Asia (Singapore) first reported a position in YMAB in Q1 2024 and held it in 3 quarters. The position peaked at $138K in Q1 2025. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Point72 Asia (Singapore) reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Point72 Asia (Singapore) sold 12,171 Y-mAbs Therapeutics shares in Q3 2025, an estimated $54.9K.
Point72 Asia (Singapore) first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 3 quarters.
Point72 Asia (Singapore)'s Y-mAbs Therapeutics position peaked at $138K in Q1 2025.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.